The resistance landscape of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer: molecular mechanisms and novel therapeutic strategies.

Transl Lung Cancer Res · 2026 · PMC13186667 · PMID 42170254

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although OS benefits were observed in the two clinical trials, extended follow-up data from NEJ009 revealed that this OS advantage did not reach statistical significance ( 181 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.